File(s) not publicly available
Endogenous erythropoietin as part of the cytokine network in the pathogenesis of experimental autoimmune encephalomyelitis
journal contributionposted on 2023-06-07, 16:04 authored by Manuela MengozziManuela Mengozzi, Ilaria Cervellini, Paolo Bigini, Sara Martone, Antonella Biondi, Rosetta Pedotti, Barbara Gallo, Sara Barbera, Tiziana Mennini, Mariaserena Boraso, Marina Marinovich, Edwige Petit, Myriam Bernaudin, Roberto Bianchi, Barbara Viviani, Pietro Ghezzi
Erythropoietin (EPO) is of great interest as a therapy for many of the central nervous system (CNS) diseases and its administration is protective in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS). Endogenous EPO is induced by hypoxic/ischemic injury, but little is known about its expression in other CNS diseases. We report here that EPO expression in the spinal cord is induced in mouse models of chronic or relapsing-remitting EAE, and is prominently localized to motoneurons. We found a parallel increase of hypoxia-inducible transcription factor (HIF)-1 alpha, but not HIF-2 alpha, at the mRNA level, suggesting a possible role of non-hypoxic factors in EPO induction. EPO mRNA in the spinal cord was co-expressed with interferon (IFN)-gamma and tumor necrosis factor (TNF), and these cytokines inhibited EPO production in vitro in both neuronal and glial cells. Given the known inhibitory effect of EPO on neuroinflammation, our study indicates that EPO should be viewed as part of the inflammatory/anti-inflammatory network in MS.
PublisherFeinstein Institute for Medical Research
Department affiliated with
- Clinical and Experimental Medicine Publications
Full text available